[go: up one dir, main page]

WO1997009061A1 - Traitement du diabete par l'administration d'insuline n'ayant pas d'effet hormonal - Google Patents

Traitement du diabete par l'administration d'insuline n'ayant pas d'effet hormonal Download PDF

Info

Publication number
WO1997009061A1
WO1997009061A1 PCT/US1996/014348 US9614348W WO9709061A1 WO 1997009061 A1 WO1997009061 A1 WO 1997009061A1 US 9614348 W US9614348 W US 9614348W WO 9709061 A1 WO9709061 A1 WO 9709061A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
hormonally
diabetes
ineffective
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/014348
Other languages
English (en)
Inventor
Yi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of WO1997009061A1 publication Critical patent/WO1997009061A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Definitions

  • Diabetes Mellitus Diabetes mellitus is the most common endocrine disease, and is characterized by abnormalities of glucose metabolism.
  • the abnormal glucose metabolism associated with this disease results in hyperglycemia (high blood glucose levels) and eventually causes complications of multiple organ systems, including eyes, kidneys, nerves, and blood vessels.
  • Patients with persistent hyperglycemia or abnormal glucose tolerance are generally diagnosed with the disease, although most commonly patients initially present with excessive urination (polyuria) and frequent drinking due to extreme thirst (polydipsia) . These typical initial symptoms result from the osmotic effects of hyperglycemia.
  • diabetes mellitus is typically associated with pancreatic dysfunction, particularly of the beta cells of the pancreatic islets of Langerhans. This dysfunction may lead to destruction of the islet beta cells, which produce insulin, a glucose regulatory peptide hormone.
  • Diabetes mellitus has been generally categorized as insulin dependent or type 1, versus non-insulin dependent, or type 2. However, this terminology has evolved as the disease has become better understood. For example, it has been found that in some patients suffering from non-insulin dependent diabetes, the disease progresses into an insulin dependent form, while in other patients insulin dependence does not develop.
  • Type 1 autoimmune islet pathogenesis, i.e., to diabetes caused by islet-specific autoimmune attack, and is ⁇ o used hereinafter.
  • IDDM insulin dependent diabetes mellitus
  • pre-IDDM refers to an autoimmune condition that can be detected by biopsy or by analysis of autoimmune responses, in which pancreatic islet beta cells are being subject to a specific autoimmune attack to an extent where some cells may be subject to destruction.
  • pre-IDDM the destruction (if any) has not progressed to an extent sufficient to require the administration of insulin. Since there can be a point in the early stages of type 1 diabetes in which overt symptoms are observed but some islet function remains, not all type 1 diabetes is classified as IDDM, and not all pre-IDDM presents without overt symptoms.
  • the metabolic complications associated with the abnormal metabolism caused by insulin insufficiency can affect numerous organ systems.
  • the most common acute metabolic complication is that of diabetic ketoacidosis, characterized by severe hyperglycemia (and resulting hypovolemia caused by osmotic diuresis) as well as metabolic acidosis induced by excess free fatty acid release and the production of ketone bodies.
  • a patient experiencing these complications may present with anorexia, nausea, vomiting and/or altered consciousness, and must be treated aggressively with insulin therapy as well as fluid and electrolyte replacement.
  • Diabetic retinopathy is a leading cause of blindness, and is initiated by increased permeability of retinal capillaries which can progress to occlusion, hemorrhage, aneurysm formation, and neovascularization known as proliferative retinopathy.
  • kidney and neurological diseases are common complications of diabetes.
  • Diabetic nephropathy causes about half of end-stage renal disease in the United States. Histologically, the nephropathy is characterized by glomerular basement membrane widening and mesangial thickening. Initial signs include increasing proteinuria, with azotemia ultimately leading to renal failure.
  • Diabetic neuropathy can affect any part of the nervous system, with the possible exception of the brain. The neuropathy is most commonly seen a ⁇ peripheral polyneuropathy, with symptoms including numbness, paresthesias, severe hyperesthesias, and pain. Autonomic neuropathy can cause gastrointestinal dysfunction, orthostatic hypotension, bladder dysfunction or paralysis, and impotence.
  • Diabetic foot ulcers represent a special problem of diabetics, and appear to be due primarily to abnormal pressure distribution secondary to diabetic neuropathy.
  • the ulcerous lesions are often worsened by concomitant peripheral vascular disease and infection.
  • meticulous control of blood glucose has been associated with amelioration of the late complications of diabete ⁇ , ⁇ uggesting that therapie ⁇ that preserve beta cell function could reduce or eliminate the majority of the complications of diabetes mellitus.
  • Type 1 diabetes only develops in genetically susceptible individuals, and symptoms generally appear before age 40, with the peak incidence of onset of overt symptomology occurring in the second decade of life.
  • the pathogenesis of type 1 diabetes is characterized by an initial phase of leukocyte ⁇ infiltration into the islets, referred to a ⁇ in ⁇ uliti ⁇ , followed over a period of time by the actual de ⁇ truction of the islet beta cells by autoimmune attack.
  • the insulitis phase is characterized by infiltration of pancreatic islets by both lymphocytes and cells of the monocyte/macrophage lineage, and entail ⁇ both cell- mediated inflammation as well a ⁇ attack by islet-specific cytotoxic antibodies.
  • T Cells The autoimmune destruction of the beta cells of the pancreatic islets in Type 1 diabetes is believed to be initiated by white blood cells (leukocytes), mo ⁇ t importantly T cell ⁇ . T cells, or T-lymphocytes, are mononuclear white blood cells that provide many essential immune functions. The importance of T cells in human autoimmune diseases has been increasingly appreciated in the past decade.
  • T cells mediate tissue injury by indirect and direct means.
  • T cell ⁇ of both CD8 + (cytotoxic) and CD4 + (helper) ⁇ ubset ⁇ secrete a variety of inflammatory cytokines that can damage tissue ⁇ indirectly by activating various other types of white blood cell ⁇ .
  • Example ⁇ of ⁇ uch T cell effects include activation of antibody ⁇ ecreting B cell ⁇ ( ⁇ timulating humoral immune activity) and activation of macrophage ⁇ , which can cau ⁇ e acute ti ⁇ sue damage and inflammation by releasing hydrolytic enzymes, reactive oxygen species, and additional pro-inflammatory cytokines.
  • direct ti ⁇ ue damage can be mediated by CD8 + cytotoxic T cells attacking cells displaying target antigen ⁇ .
  • T cell receptors T cell receptors
  • TCRs membrane bound antibody-like binding structures
  • TCR ⁇ bind with high specificity to particular antigens.
  • antibody-producing cell ⁇ which develop as multitudinous clones of cells, each clone producing antibodies with unique specificities, T cells develop as a vast number of distinct clones, and any particular T cell clone expresses a single type of TCR with a defined binding specificity.
  • T cell clones with TCRs that bind specifically to self antigens are respon ⁇ ible for the development of autoimmune di ⁇ eases.
  • a particular polypeptide antigen typically comprises numerous ⁇ ubmolecular features, known as epitopes, that each can serve a ⁇ a di ⁇ tinct binding site for a particular antibody or TCR.
  • T cell clones reactive with various epitopes of a small number of autoantigens, become activated and are involved in pathogenesis. Even in individuals suffering from autoimmune diseases, only a small subset of T cell clones (0.1-1%) are known to recognize autoantigens.
  • Variou ⁇ mechanism ⁇ have been po ⁇ tulated to play a role in the pathogenic activation of disea ⁇ e-cau ⁇ ing autoreactive T cell ⁇ .
  • Primary activation of antigen presenting cells (APCs) by infection or local inflammation is implicated in one such mechanism.
  • APCs activated in this way can then provide powerful co-stimulation for hitherto unreactive T cells.
  • T cell-mediated autoimmune disease In addition to external factors, underlying the emergence of all T cell-mediated autoimmune disease is a complex pattern of inherited susceptibility determined by multigenic factors. For further di ⁇ cus ⁇ ions of these various factors, Steinman, 1995, reviews current theories of autoimmunity.
  • Apoptosi ⁇ thu ⁇ play ⁇ a large role in shaping and maintaining the T cell repertoire and contributes to the establishment of self- tolerance by actively eliminating cells expressing autoreactive TCRs.
  • T cells are sensitive to apoptotic cell death induced by a variety of stimuli at multiple points in their life ⁇ pan (see, for example, Lenardo 1991; Boehme and Lenardo 1993; Critchfield et al. 1994) .
  • Positive selection factors are also believed to play a role in regulating the survival of specific T cell clones.
  • the reduction or expansion of the number of individual T cells of a particular clone in an organism by these and other mechanisms serve to modulate the responsivenes ⁇ of the organi ⁇ m's immune sy ⁇ tem to a particular antigen.
  • Apoptosis occurs in many biological sy ⁇ tem ⁇ (see, for example, Kerr et al. 1991; Lock ⁇ hin and Zakeri, 1991; Cohen et al. 1992; Duvall and Wyllie, 1986; Cotter et al. 1990) .
  • a cell undergoing apopto ⁇ i ⁇ undergoe ⁇ a ⁇ pecific program of event ⁇ -- cellular and biochemical proce ⁇ e ⁇ that depend upon active metaboli ⁇ m and contribute to the cell's self-de ⁇ truction.
  • apoptotic T cell ⁇ In apoptotic T cell ⁇ , the nucleus shrinks, the chromatin condenses, the genetic material (DNA) progressively degrades into ⁇ mall (nucleo ⁇ omal repeat ⁇ ized) fragment ⁇ , there i ⁇ cytopla ⁇ mic compaction, the cell membrane forms blebs, and the cell eventually collapses (Kawabe and Ochi, 1991; Smith et al. 1989) . Cells cannot recover from apoptosis, it results in irreversible cell death (Kawabe and Ochi, 1991; Smith et al. 1989) .
  • TNF-related cytokine known as the FAS ligand and its receptor, CD95 (the FAS receptor)
  • CD95 the FAS receptor
  • T cells that do not undergo apoptosis, but which have become activated will carry out their "effector" functions by causing cytolysis, or by secreting lymphokine ⁇ that cau ⁇ e B cell response ⁇ or other immune effect ⁇ (Paul, 1989) .
  • effector functions are the cause of tissue damage in autoimmune and other diseases.
  • Type 1 diabetes is con ⁇ idered to be mediated by T cell ⁇ .
  • the di ⁇ ease is believed to be a consequence of inappropriate ⁇ pecific T cell responses to certain islet beta cell proteins that act as autoantigens.
  • autoantibodies against variou ⁇ self antigens have also been reported in IDDM patients.
  • the antigens reported to be bound by these autoantibodie ⁇ include many of those that have been reported to be recognized by autoreactive T cells.
  • Autoantigens that are subject to autoimmune respon ⁇ es in Type 1 patients include ⁇ ialyglycolipid; the 64kDa and 67kDa GAD (glutamate decarboxyla ⁇ e) autoantigen ⁇ ; insulin; a 38kD antigen from the secretory granule ⁇ of beta cells; an antigen cros ⁇ reactive with antibodies to bovine albumin known a ⁇ the beta cell p69 protein, PM-1, or di ⁇ ease-modifying antigen, a beta cell cyto ⁇ keletal protein known as peripherin, gluco ⁇ e tran ⁇ porter proteins, including GLUT-2 ,* heat shock protein 65 (HSP 65) , including the p277 peptide; carboxypeptida ⁇ e H; a 52Kd molecular mimic of Rubella viru ⁇ antigen; a beta cell membrane a ⁇ sociated protein of 150kDa; a protein antigen located at the secretory pole of the rat insulinoma cell line RINm38, referred
  • modulation of insulin reactive T cells would be closing the barn door after the horses had gone, the anti-insulin reactions being observed so late in disease progression that their modulation would not be expected to affect the onset or severity of di ⁇ ea ⁇ e.
  • T cells also respond to other islet cell antigens.
  • the ⁇ e include a 38kD antigen from the ⁇ ecretory granule ⁇ of beta cells, and serum albumin.
  • heat shock protein 65 has been implicated based upon the fact that HSP-specific T cells were shown to transfer disease in NOD mice.
  • Carboxypeptidase H i ⁇ a molecule found in islet secretory granules and is associated with the production of peptide hormone ⁇ and neurotran ⁇ mitter ⁇ . It was identified as a potential islet autoantigen by the screening of cDNA expression libraries with sera from IDDM or pre-IDDM patient ⁇ .
  • ICA12 and ICA512 have also been identified by screening of cDNA expression libraries.
  • Insulin autoantibodies can be detected in around 50% of new onset patients, and are highly associated with islet cell autoantibodies (ICA) and the HLA-DR4 phenotype.
  • ICA islet cell autoantibodies
  • T cell responses to insulin as autoantigen have al ⁇ o been de ⁇ cribed.
  • cellular responses to human insulin were present in almost 90% of ICA-positive first degree relatives of IDDM patients.
  • insulin reactive T cells from diabetic NOD mice can tran ⁇ fer diabetes to non-diabetic NOD mice.
  • Type 1 Disease As discus ⁇ ed above, there i ⁇ a genetic aspect to the incidence of type 1 diabetes. Accordingly, individuals with a known family history of the di ⁇ ea ⁇ e can be monitored for early, preclinical ⁇ igns of disease development, e.g., by monitoring levels of the autoantibodies discu ⁇ sed herein. In addition, genetic tests can identify certain individuals at increased ri ⁇ k of developing the disease (see, for example, Walston et al . 1995) .
  • Prediction of type 1 diabetes may also be facilitated by monitoring of the subject's blood sugar levels, preferably, in conjunction with the administration of a glucose tolerance test to the subject. Such procedures are preferably carried out in combination with the monitoring of titers of the subject's circulating autoantibodies, such autoantibodies selected from the group consi ⁇ ting of IAA, ICA, and GAD ⁇ pecific autoantibodie ⁇ .
  • the first line of treatment is diet, with appropriate caloric intake based on ideal body weight and a defined distribution among protein, glucose, and fat.
  • the most important component of therapy is the administration of insulin, the goal of which is to maintain glucose levels as clo ⁇ e to the normal range a ⁇ possible throughout the day.
  • Insulin is available in rapid, intermediate, and long-acting formulations which vary in onset, peak, and duration of action, and can be u ⁇ ed in varying ⁇ chedule ⁇ of admini ⁇ tration to attempt to optimally regulate plasma glucose levels.
  • Intensive insulin therapy refer ⁇ to a rigorou ⁇ regimen of admini ⁇ tration of hormonally effective in ⁇ ulin and monitoring of blood ⁇ ugar levels.
  • Thi ⁇ regimen is designed to control blood gluco ⁇ e as precisely as pos ⁇ ible.
  • the re ⁇ ult ⁇ of the multicenter Diabetes Control and Complication Trial established that complications of diabete ⁇ are ⁇ ignificantly diminished by better control of blood glucose level ⁇ , and thu ⁇ demon ⁇ trated the desirability of intensive insulin therapy.
  • intensive insulin therapy requires a high level of patient awareness and compliance, a ⁇ well as a highly skilled care team of physicians, nurses, and dietitians. The goals of intensive insulin therapy are thus extremely difficult to achieve, even with motivated and educated patients.
  • Another problem is that a higher rate of hypoglycemia is seen in such rigorously treated patients than in patient ⁇ receiving standard, less rigorous, in ⁇ ulin regimen ⁇ .
  • the Diabetes Control and Complication Trial highlighted not only the benefit to overall metabolic health of maintaining normal blood glucose levels, but al ⁇ o a fundamental problem a ⁇ ociated with the treatment of type 1 diabetes, namely that the overt symptoms of the disease are manifested only when essentially all of the patients' islets are destroyed.
  • Oral agents for diabetes such a ⁇ the sulfonylureas, act primarily by stimulating the release of insulin from dysfunctional beta cells, and thus are not useful for most patients with type 1 disease, i.e. for those patients with IDDM.
  • a major unmet goal in the treatment of diabete ⁇ has been to develop a therapy capable of aborting the autoimmune attack on the islet beta cells prior to their complete destruction, thereby preserving enough endogenous function to maintain normal metabolic control. Induction of tolerance.
  • NOD non-obe ⁇ e diabetic
  • mou ⁇ e model of diabete ⁇ it has been shown that oral feeding of insulin delayed the onset and reduced the severity of the disease.
  • the mechanism proposed to explain oral tolerance is that oral antigen administration induce ⁇ populations of antigen-specific Th2 T cells that secrete antiinflammatory cytokines such as IL-4, IL-10, and TGF-beta.
  • T cells circulate and are activated to secrete cytokines only in the presence of their ⁇ pecific antigen. Thu ⁇ , in ⁇ ulin- specific Th2 T cells would be activated only in the pancreas where they would produce ⁇ uppre ⁇ ive cytokines to modulate the autoimmune process. This mechanism does not require, therefore, that the oral antigen actually represent a disea ⁇ e-specific autoantigen, but rather only that it is expressed in a tis ⁇ ue specific fashion.
  • method ⁇ de ⁇ igned to produce T cell tolerance require the identification of the actual disea ⁇ e-specific autoantigens that are targeted by autoimmune attack. Such antigens are then admini ⁇ tered to patient ⁇ in an appropriate tolerizing fashion (which may al ⁇ o induce non-antigen-specific tolerizing effects) .
  • type 1 diabetes is in significant measure a disea ⁇ e mediated by islet-specific autoreactive T cells, therapy of this type ⁇ hould be fea ⁇ ible in principle. Thu ⁇ , induction of neonatal tolerance to GAD, a ⁇ referred to above, prevented on ⁇ et of di ⁇ ea ⁇ e in NOD mice.
  • Apopto ⁇ i ⁇ is a form of programmed cell death that occurs in many biological systems (Kerr et al. , 1991. Apoptosis: The molecular basi ⁇ of cell death, Tomei and Cope (eds.), Cold Spring Harbor Laboratory Press, Plainview, New York, pp. 5; Lock ⁇ hin and Zakeri, 1991. supra, pp. 47; Cohen et al . , 1992. Ann Rev Immunol 10, pp. 267; Duvall and Wyllie, 1986. Immunol Today 7, pp. 115; Cotter et al. , 1990. Anticancer Research 10, pp. 1153) .
  • apoptotic cell undergoes a ⁇ pecific program of event ⁇ that depend upon active metabolism and contribute to its own self-destruction.
  • the nucleus shrinks, the genetic material (DNA) gradually ⁇ ively degrade ⁇ , and the cell eventually collap ⁇ e ⁇ (Kawabe and Ochi, 1991. Nature 349, pp. 245-248; Smith et al. , 1989. Nature 337, pp. 181-184) .
  • Cell ⁇ cannot recover from apopto ⁇ is, it result ⁇ in irrever ⁇ ible killing (Kawabe and Ochi, 1991. Nature 349, pp. 245-248; Smith et al., 1989. Nature 337, pp. 181-184) .
  • T cell ⁇ that do not undergo apopto ⁇ i ⁇ , but which have become activated will carry out their "effector” function ⁇ by cau ⁇ ing cytoly ⁇ i ⁇ , or by ⁇ ecreting lymphokines that cau ⁇ e B cell responses or other immune effects (Paul, 1989. Fundamental Immunology, 2nd Ed. Paul (ed.), Raven Pres ⁇ , New York, pp. 3-38) .
  • effector functions are the cau ⁇ e of ti ⁇ ue damage in autoimmune and other di ⁇ ease ⁇ .
  • a powerful approach to avoiding disease is thus to permanently eliminate by apoptosis only those T cells reactive with autoimmune disease-inciting antigens, while leaving the majority of the T cell repertoire intact.
  • Figure 1 shows the results of the CYTOXAN induced IDDM experiments .
  • Figure 2 show ⁇ the re ⁇ ult ⁇ of the adoptive tran ⁇ fer of IDDM experiment ⁇ .
  • the objects of this invention are to provide novel immunomodulatory methods for both the prevention and treatment of type 1 diabetes mellitus.
  • the invention provides a method of treating a patient in need of such treatment, e.g., a patient selected from the group of patients consisting of patients at risk of developing diabetes and patients suffering from diabetes (particularly early in disease progression before all of the patient's beta cells have been destroyed by the disease), so as to delay the onset or reduce the symptoms of diabetes in the patient.
  • This method comprises the administration of do ⁇ e ⁇ containing mea ⁇ ured amounts of an adjuvant free hormonally ineffective insulin related polypeptide to the patient.
  • thi ⁇ admini ⁇ tration is carried out on a therapeutic T cell modulatory schedule, i.e., a schedule designed to induce apoptosis, anergy, or other modulation of the autoimmune activity of T cells reactive with at least one epitope of the hormonally ineffective insulin related polypeptide.
  • a therapeutic T cell modulatory schedule i.e., a schedule designed to induce apoptosis, anergy, or other modulation of the autoimmune activity of T cells reactive with at least one epitope of the hormonally ineffective insulin related polypeptide.
  • the measured amounts are superphy iologic amount ⁇ . While not wi ⁇ hing to be bound by any particular theory of action or operation, the inventor ⁇ believe that administration of doses containing superphysiologic amounts of hormonally ineffective insulin related polypeptides on a therapeutic T cell modulatory schedule in accordance with their invention results in particularly beneficial effects on the development and severity of type 1 diabetes.
  • Doses containing superphysiologic amounts of a hormonally ineffective insulin related polypeptide mean ⁇ do ⁇ e ⁇ providing amounts of a hormonally ineffective insulin related polypeptide, or of a combination of hormonally ineffective insulin related polypeptides, that would cause insulin ⁇ hock if the in ⁇ ulin related polypeptide( ⁇ ) were hormonally effective.
  • a superphy ⁇ iologic amount contains a number of moles of the hormonally ineffective in ⁇ ulin related polypeptide equal to or greater than the number of moles of hormonally effective insulin that will induce insulin shock in the patient.
  • the hormonally ineffective insulin related polypeptide is preferably ⁇ elected from the group con ⁇ i ⁇ ting of pre-pro insulin, proin ⁇ ulin, denatured in ⁇ ulin, in ⁇ ulin chain B, in ⁇ ulin chain A, and in ⁇ ulin chain C, either a ⁇ whole polypeptides or fragments of these polypeptides. Combinations of these polypeptides may also be administered in accordance with the present invention as long as their combination does not generate a hormonally effective insulin polypeptide. Particular ⁇ of ⁇ uch hormonally ineffective in ⁇ ulin related polypeptides are discussed below under the heading "Detailed Description of the Preferred Embodiments.”
  • the hormonally ineffective in ⁇ ulin related polypeptide (or polypeptides) used in the practice of the present invention is preferably a form or fragment of an insulin molecule comprising an amino acid ⁇ equence of at lea ⁇ t 6, and preferably 10 con ⁇ ecutive amino acid ⁇ that are in a ⁇ equence identical to that of the ⁇ equence of an insulin molecule that is hormonally effective. More preferably the hormonally ineffective insulin polypeptide is selected from the group con ⁇ isting of pre-pro insulin, proinsulin, denatured in ⁇ ulin, insulin chain B, insulin chain A, and insulin chain C, either as whole polypeptides or as fragments of these polypeptides.
  • a particularly preferred hormonally ineffective insulin related polypeptide for use in the present invention comprises insulin Chain B. Most preferred is in ⁇ ulin Chain B that i ⁇ ⁇ ubstantially free of other insulin chains.
  • hormone ineffective refer ⁇ to hormonal effectivene ⁇ s in a patient, preferably a human patient, although such effectivene ⁇ i ⁇ conveniently mea ⁇ ured u ⁇ ing the rabbit blood- ⁇ ugar method (USP biological te ⁇ t ⁇ 121>, USP 23 / NF 18 1995) .
  • suitable assays of the hormonal activity of insulin are known in the art, and may be used if desired to determine the level of hormonal effectiveness or ineffectivenes ⁇ of a particular preparation of one or more in ⁇ ulin related polypeptide ⁇ .
  • Hormonally ineffective in ⁇ ulin polypeptide ⁇ ⁇ uitable for use in the practice of the present invention can be prepared by conventional mean ⁇ well known in the art, including: purification from natural ⁇ ource ⁇ (i.e., from animal pancreases, e.g.
  • hormonally effective insulin ⁇ may be prepared by any of the various means known in the art, and may then be inactivated, preferably by denaturation (followed by chain separation, if desired) .
  • Denaturation of hormonally effective insulin ⁇ to produce hormonally ineffective insulin polypeptides may be carried out by any method of denaturation, a large variety of which are known to those of skill in the art. These include heat denaturation, various types of chemical denaturation (e.g., using chaotropic agents such as urea or guanidinium HCl, or other chemical means of denaturation such as carboxymethylation) . Denaturation of in ⁇ ulin related polypeptide ⁇ produced by ⁇ ynthetic or recombinant DNA method ⁇ may al ⁇ o be achieved by ⁇ equence truncation or in ⁇ ulin precursor ⁇ ynthesi ⁇ in organi ⁇ m ⁇ incapable of proce ⁇ ing the precursor to produce mature, hormonally effective insulin.
  • combinations of these hormonally ineffective insulin related polypeptides may also be u ⁇ ed in the practice of the pre ⁇ ent invention as long as their combination does not generate a hormonally effective in ⁇ ulin polypeptide.
  • a ⁇ used herein a hormonally ineffective insulin related polypeptide has le ⁇ hormonal activity than the minimum activity for insulin required by the United States Pharmacopea (USP 23 / NF 18, 1995) , which is 26 USP units per milligram. Therefore, in accordance with the present invention, any insulin related polypeptide exhibiting 25 USP unit ⁇ of in ⁇ ulin activity per milligram or le ⁇ i ⁇ considered to by hormonally ineffective.
  • the hormonally ineffective insulin related polypeptide has les ⁇ than 20 USP unit ⁇ of activity per mg, more preferably less than 10 USP units per mg, and most preferably les ⁇ than 5 USP unit ⁇ of in ⁇ ulin activity per mg of polypeptide.
  • doses containing superphysiologic amounts of hormonally ineffective insulin related polypeptide ⁇ mean ⁇ doses containing amounts providing at least an equivalent number of mole ⁇ of hormonally ineffective insulin related polypeptide to the number of moles of hormonally effective insulin that will induce insulin ⁇ hock in the patient.
  • such superphy ⁇ iologic amounts of hormonally ineffective insulin related polypeptide ⁇ compri ⁇ e amounts ranging from about 6.9 pM/kg/patient to about 8.6 ⁇ M/kg/patient.
  • the amounts range from about 34.5 pM/kg/patient to about 5.2 ⁇ M/kg/patient. More preferably the amounts range from about 170 pM/kg/patient to about 3.5 ⁇ M/kg/patient.
  • Most preferably the amounts range from about 0.5 ⁇ M/kg/patient to about 3.5 ⁇ M/kg/patient.
  • the present invention also provides for the repeated adjuvant free administration of doses containing lower (not superphy ⁇ iologic) amounts of hormonally ineffective insulin related polypeptides to a patient in need of ⁇ uch treatment.
  • doses containing amounts of below about 6.9 pM/kg/patient, and as low as about 1 pM/kg/patient may be u ⁇ ed in the practice of the pre ⁇ ent invention.
  • ⁇ uch lower amounts are referred to as "physiologic doses" or "physiologic amounts” when they contain a number of moles of hormonally ineffective insulin related polypeptide that is less than the number of moles of hormonally effective insulin that will induce insulin shock in the patient, but contain at least about 1 picomole of hormonally ineffective insulin related polypeptide, i.e., at least as many mole ⁇ of in ⁇ ulin related polypeptide as there are moles of insulin in about 0.15 USP units of insulin with a specific activity equal to the USP minimum activity standard of 26 units per mg (the equivalent of about 5.8 ug of human insulin with that specific activity) .
  • a therapeutic T cell modulatory schedule involves administration of doses containing superphy ⁇ iologic amounts of the hormonally ineffective in ⁇ ulin polypeptide ⁇ repeatedly to the patient at least two times at an interval of at least six, and preferably at least twelve hours and not more than seven days between doses.
  • the polypeptides are administered parenterally without the concomitant administration of an adjuvant.
  • Administration by a parenteral route will typically be via injection such as intravascular injection (e.g., intravenous infusion), subcutaneous injection, or intramuscular injection.
  • Other non- oral routes of administration e.g., mucosal, inhalation, transdermal ultrasound, and the like, may be used if desired and practicable for the particular hormonally ineffective insulin related polypeptide to be administered.
  • Formulations suitable for injection and other routes of administration are well known in the art and may be found, for example, in Remington's Pharmaceutical Sciences. Mack Publi ⁇ hing Company, Philadelphia, PA, 17th ed. (1985) .
  • Preferred formulations for parenteral administration of hormonally ineffective insulin related polypeptides are those described for insulin in the USP 23/NF 18 (1995) .
  • Parenteral formulations mu ⁇ t be ⁇ terile and non-pyrogenic, and generally will include a pharmaceutically effective carrier, ⁇ uch a ⁇ saline, buffered (e.g., phosphate buffered) saline, Hank' ⁇ ⁇ olution, Ringer's solution, dextrose/saline, glucose solutions, and the like.
  • Formulations may al ⁇ o contain pharmaceutically acceptable auxiliary ⁇ ub ⁇ tances as required, such as, tonicity adjusting agent ⁇ , wetting agent ⁇ , bactericidal agents, preservatives, stabilizers, and the like.
  • Non-obese diabetic mice are a strain of mice that are prone to the development of diabetes, and repre ⁇ ent an accepted model system for the study of diabetes mellitus.
  • NOD SCID mice de ⁇ ignated NOD/SCID, are available from the Jack ⁇ on Laboratorie ⁇ , Bar Harbor, ME. The incidence of diabete ⁇ by 200 day ⁇ of age in these mice is 80% in females and 50% in males. At 110 days of age, fewer than 15% of the male NOD mice became diabetic.
  • CYTOXAN Cyclophosphamide
  • CYTOXAN Cyclophosphamide
  • mice All the mice were subjected to urine gluco ⁇ e mea ⁇ urement 2- 3 times per week for a period of 21 days after cyclophosphamide injection. The onset of diabetes was recorded as the first point at which two consecutive days of po ⁇ itive urine glucose result ⁇ were obtained. Blood glucose was also measured to confirm the urine glucose re ⁇ ults. (ExacTech, MediSense Inc., Cambridge, MA) In all the mice tested with po ⁇ itive urine gluco ⁇ e, blood gluco ⁇ e level ⁇ were greater than 150mg/dl. At day 21, the ⁇ e mice were ⁇ acrificed and examined hi ⁇ tologically.
  • Oxidized bovine insulin Chain B was purchased from Sigma (catalog no. 1-6383) . Both insulin chain B and the BSA control protein (Miles Inc., #81-001) were dissolved in PBS/1M HCL, pH2, before dialysi ⁇ against PBS, pH7.2, sterile filtration, and storage of frozen aliquots. Treatment;
  • In ⁇ ulin Chain B treatment in the CYTOXAN model Groups of randomly selected NOD mice were injected intravenously twice daily with either 500ug insulin Chain B or 500ug BSA on day ⁇ 1, 3, and 5 following CYTOXAN treatment (day 0) .
  • In ⁇ ulin Chain B treatment in the adoptive tran ⁇ fer model NOD/SCID mice were injected intravenously twice daily with 500ug of in ⁇ ulin Chain B (or BSA as control) on day 3, 5 and 7 relative to the time of spleen cell transfer (day 0) .
  • Table-1 do ⁇ e dependency of cyclophosphamide induced diabetes in non-diabetic male NOD recipients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé immunomodulateur pour prévenir et traiter le diabète sucré du type I. Ce procédé consiste à administrer au patient des doses contenant des quantités mesurées (de préférence superphysiologiques) d'un polypeptide lié à l'insuline, sans effet hormonal et sans adjuvant. L'administration de ces doses se fait de préférence selon un programme destiné à induire une apoptose, une anergie, ou une autre modulation de l'activité auto-immunitaire des cellules T réagissant avec au moins un épitope du polypeptide lié à l'insuline et sans effet hormonal. Ce polypeptide lié à l'insuline et sans effet hormonal est de préférence choisi dans un groupe composé de pré-proinsuline, de proinsuline, d'insuline dénaturée, de la chaîne B de l'insuline, de la chaîne A de l'insuline, de la chaîne C de l'insuline, soit sous forme de polypeptide entier, soit sous forme de fragments. Des combinaisons de ces polypeptides peuvent être également administrées pour autant que leur combinaison ne crée pas de polypeptide avec effet hormonal. L'administration desdits polypeptides liés à l'insuline et sans effet hormonal a des effets bénéfiques sur le développement du diabète du type I, et en atténue la gravité.
PCT/US1996/014348 1995-09-06 1996-09-05 Traitement du diabete par l'administration d'insuline n'ayant pas d'effet hormonal Ceased WO1997009061A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US328595P 1995-09-06 1995-09-06
US60/003,285 1995-09-06
US56576995A 1995-12-01 1995-12-01
US08/565,769 1995-12-01

Publications (1)

Publication Number Publication Date
WO1997009061A1 true WO1997009061A1 (fr) 1997-03-13

Family

ID=26671585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/014348 Ceased WO1997009061A1 (fr) 1995-09-06 1996-09-05 Traitement du diabete par l'administration d'insuline n'ayant pas d'effet hormonal

Country Status (1)

Country Link
WO (1) WO1997009061A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274549B1 (en) 1995-06-30 2001-08-14 Novo Nordisk A/S Treatment of type 1 diabetes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006704A1 (fr) * 1990-10-10 1992-04-30 Autoimmune, Inc. Methodes servant a traiter ou a prevenir le diabete du type 1 par administration orale d'insuline
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006704A1 (fr) * 1990-10-10 1992-04-30 Autoimmune, Inc. Methodes servant a traiter ou a prevenir le diabete du type 1 par administration orale d'insuline
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAN. MED. ASSOC. J., 15 November 1991, Vol. 145, No. 10, RODGER, W. "Insulin-Dependent (Type I) Diabetes Mellitus", pages 1227-1237. *
CLINICAL RESEARCH, 1983, Vol. 31, No. 2, SHIPP et al., "Severe Insulin Resistance in Patient With Type I Diabetes Responsive Only to Intraperitoneal Insulin: A New Syndrome?", page 546A. *
DIABETES, May 1985, Volume 34, Supplement 1, NIPPE et al., "Intraperitoneal (IP) Versus Intravenous (IV) Application of Human Proinsulin and Insulin in Type I Diabetics", page 59A, Abstract 236. *
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 1984, Vol. 58, No. 6, BERGENSTAL et al., "The Metabolic Effects of Biosynthetic Human Proinsulin in Individuals With Type I Diabetes", pages 973-979. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274549B1 (en) 1995-06-30 2001-08-14 Novo Nordisk A/S Treatment of type 1 diabetes

Similar Documents

Publication Publication Date Title
US7384915B2 (en) Chimeric insulin-gad proteins for treating patients with type 1 diabetes or at risk of developing type 1 diabetes
Warnock et al. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus
Zangen et al. Reduced insulin, GLUT2, and IDX-1 in β-cells after partial pancreatectomy
DE60026332T2 (de) Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen
USRE41887E1 (en) Treatment of autoimmune disease
DE69430868T2 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
JPH09503387A (ja) クローン化されたグルタミン酸デカルボキシラーゼ
US6921751B1 (en) Immunoregulator
Pilström et al. Demonstration of a TH1cytokine profile in the late phase of NOD insulitis
Gray et al. Islet cell transplantation for insulin-dependent diabetes mellitus: perspectives from the present and prospects for the future
EP0999848B1 (fr) Proteines chimeres pour le traitement du diabete
CA2328529A1 (fr) Immunoregulateur
JP2739770B2 (ja) インスリン依存性糖尿病の予防または治療のためのｉｌ−１０の使用
EP0655927B1 (fr) Elimination de cellules de lymphocytes t par l'intermediaire d'interleukine-4
WO1997009061A1 (fr) Traitement du diabete par l'administration d'insuline n'ayant pas d'effet hormonal
JPH06298662A (ja) 自己免疫疾患の予防治療剤
Svenningsen et al. Insulin release and pancreatic insulin is reduced in young prediabetic BB rats
AU690234B2 (en) Peptides and methods against diabetes
Warnock et al. Human pancreatic islet transplantation
PRAISSMAN et al. A reduced pancreatic protein secretion in response to cholecystokinin (CCK) in the obese Zucker rat correlates with a reduced receptor capacity for CCK
Thivolet New therapeutic approaches to type 1 diabetes: from prevention to cellular or gene therapies.
Pozzilli et al. Immunotherapy at clinical diagnosis of insulin-dependent diabetes an approach still worth considering
US20200046700A1 (en) Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
AU783594B2 (en) Method of prophylaxis and treatment of diabetes
TW202315884A (zh) 使用衍生自患者之抗原特異性調節ｔ細胞的個體化細胞療法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase